Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Parexel | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a study to evaluate the effects of AZD8871 in patients with COPD. Adult male or female patients with moderate to severe COPD, who agree to be in this study, will receive 3 treatments, i.e. 2 different doses of AZD8871 and placebo (dummy medication containing no drug) at once a day for 2 weeks, in a random order. To make the comparison between AZD8871 and placebo as fair as possible, this study is "double blinded." This means that neither patient nor the study doctor will know in which order the 3 treatments will be given. This study will include patients who are between 40 and 80 years of age. In total there will be 42 patients participating in this study at two study centers in the United Kingdom and Germany. The study will have a total of 12 visits for each patient spanning for a period of 4 to 6 months. The study is anticipated to run for approximately 8 months and should not exceed 10 months.
This is a proof-of-concept, randomised, double-blind, placebo-controlled, 3-way, complete crossover William's design, multiple dose study to investigate the efficacy, PK, safety, and tolerability of 2 dose levels of AZD8871 and placebo, administered using a dry powder inhaler (DPI) device once daily, for 2 weeks, in patients with moderate to severe COPD. AZD8871 is a new chemical entity with the combined properties of a LAMA and a LABA in a single molecule. AZD8871 is being developed as an inhaled long-acting bronchodilator for the maintenance treatment of COPD.
The objective of the study is to assess the efficacy, safety and PK of AZD8871 after a 14-day treatment period at 2 different doses in patients with moderate to severe COPD. The target population includes male and female (non-childbearing potential) adult patients with clinical diagnosis of moderate to severe COPD. The crossover design has been chosen to avoid inter-patient variability and optimize sample size. By randomly assigning treatment sequence, differences in baseline characteristics of the treatment groups will be minimised. The inclusion of a placebo arm is considered the most reliable method to minimise patient and Investigator bias. The proposed dose levels of AZD8871 in this study are 100 and 600 µg of AZD8871 given by inhalation once daily for 14 days through a single dose DPI. Doses have been selected based on the safety, tolerability, PK and pharmacodynamics (PD) information generated in previous clinical trials with AZD8871. The wash-out period proposed for this current study is a minimum of 28 days and up to 35 days in order to avoid any carry over effect between periods. The broad dose range selected (6 fold range from 100 to 600 µg) has been chosen to span the likely therapeutic dose and facilitate the dose selection for future studies. Considering the expected efficacy in patients with COPD and the available data to date, it is anticipated the benefits will outweigh the risks and support the continued investigation of AZD8871 in clinical studies.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AZD8871 100 µg | Experimental | The subjects will receive AZD8871 100 µg once daily, by dry powder inhaler (DPI) device. The treatment will be administered via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products. |
|
| Placebo | Placebo Comparator | The placebo will be administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient will receive one inhaled dose from placebo DPI provided to him/her on each day of the treatment period. |
|
| AZD8871 600 µg | Experimental | The subjects will receive AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD8871 100 µg | Drug | The subjects will receive one dose of AZD8871 100 µg single dose DPI. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in trough FEV1 on Day 15 | On Day 15 |
| Measure | Description | Time Frame |
|---|---|---|
| Observed Maximum Plasma (Cmax) of AZD8871 and Its Metabolites (Single Dose) | Observed maximum concentration, taken directly from the individual concentration-time curve, on Day 1 of each treatment period. | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1. |
| Observed Maximum Plasma (Cmax) of AZD8871 and Its Metabolites (Multiple Doses, Day 14) |
Not provided
Inclusion Criteria:
Patient who provided of informed consent prior to any study-specific procedures
Male or female 40 to 80 years of age (both inclusive) at Screening (Visit 1). A female is eligible to enter and participate in the study if she is of non-childbearing potential.
Note: A female is considered to be of non-childbearing potential if she meets one of the following criteria:
Male patient should use a condom and spermicide to prevent pregnancy and drug exposure of a partner, regardless of the gender or childbearing potential of the partner from the day of the first administration of the investigational product (IP) until 3 months after the last administration of the IP.
COPD Diagnosis: Patient with an established clinical history of COPD for more than 1 year at Screening, according to the Global Initiative for Chronic Obstructive Lung Disease 2016 COPD guidelines.
Tobacco Use: Patient is a current or former smoker with a history of ≥10 pack-years of cigarette smoking. A former smoker is defined as one who has stopped smoking for at least 6 months prior to Screening.
Patient with post-bronchodilator FEV1/FVC (Forced vital capacity) ratio <70% based on the value reached after inhalation of salbutamol (400 µg) at Visit 2. If criterion is not met, the test can be repeated at the latest, up to Day 14.
Patient with post-bronchodilator FEV1 that must be ≥40% and <80% predicted normal value and must also be >750 mL at Visit 2. If criterion is not met, the test can be repeated at the latest, up to Day 14.
Patient who fulfils reversibility criteria to salbutamol at Visit 2. Reversibility is defined as ≥12% and ≥200 mL increase in FEV1 after inhalation of 4 puffs of salbutamol. (400 µg). If criterion is not met, the test can be repeated at the latest, up to Day 14.
Patient is willing and, in the opinion of the Investigator, able to change current COPD therapy as required by the protocol and willing to use ipratropium Four times a day (if needed, during run-in and wash-out periods) with or without Inhaled corticosteroid for maintenance therapy of COPD and as needed rescue salbutamol from Visit 1 up Visit 11.
Patient is free from any clinically active disease other than COPD that may impact study outcome, as determined by medical history, physical examination, laboratory testing, and 12-lead ECG findings, at Screening.
Patient is willing to remain at the study centre as required per protocol to complete all visit assessments.
Patient with body mass index (BMI) <40 kg/m2 at the time of screening.
Exclusion Criteria:
Patient previously enrolled in the present study.
Patient has significant diseases other than COPD, ie, disease or condition or an abnormality in laboratory, ECG, medical history or physical examination which, in the opinion of the Investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the patient'spatient's ability to participate in the study.
Childbearing potential female, pregnant or lactating.
Patient who, in the opinion of the Investigator, has a current diagnosis of asthma.
Patient has alpha-1 antitrypsin deficiency as the cause of COPD.
Patient has other active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary hypertension, or uncontrolled sleep apnoea. Allergic rhinitis is not exclusionary.
Lung surgery for volume reduction or lung transplantation: Patient has undergone lung volume reduction surgery, lobectomy, or bronchoscopic lung volume reduction (endobronchial blockers, airway bypass, endobronchial valves, thermal vapour ablation, biological sealants, massive pulmonary embolism and airway implants) within 1 year of Screening (Visit 1).
Patient is using nocturnal positive pressure (eg, continuous positive airway pressure or bi level positive airway pressure). Patient is using any non-invasive positive pressure ventilation device.
Note: A patient using continuous positive airway pressure or bi level positive airway pressure for Sleep Apnoea Syndrome is allowed in the study.
Patient has been hospitalised due to poorly controlled COPD within 3 months of Screening.
Patient has acute worsening of COPD that requires treatment with corticosteroids or antibiotics in the 6 week interval prior to Screening (Visit 1), or during the Screening Period (between Visits 1 and 3).
Patient has had lower respiratory tract infections that required antibiotics within 6 weeks prior to Screening.
Patient cannot perform acceptable spirometry, ie, meet American Thoracic Society (ATS)/European Respiratory Society (ERS) acceptability criteria.
Patient has changed their smoking status (ie, start or stop smoking) or initiation of a smoking cessation program within 6 weeks prior to Screening.
Patient has participated in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening or who will enter the acute phase of a pulmonary rehabilitation program during the study. A patient in the maintenance phase of a pulmonary rehabilitation program is not to be excluded.
Cardiac disease: Subject with significant cardiovascular disease cardiovascular instability. Patient with heart rate <50 beats per minute. Patient has clinically significant uncontrolled hypertension as assessed by the investigator.
Neurological: Patient with seizures or history of seizures requiring anticonvulsants within 12 months prior to Screening. Patient is taking selective serotonin reuptake inhibitors or serotonin--norepinephrine reuptake inhibitors whose dose has not been stable for at least 4 weeks prior to Screening, or exceeds the maximum recommended dose.
Renal: Patient with symptomatic bladder neck obstruction, acute urinary retention or symptomatic non-stable prostate hypertrophy. 35.23. Patient with a serum potassium value <3.5 mmol/L at Screening and on repeat testing. Note: however potassium replacement and rescreening is allowed if serum potassium concentration was < 3.5mmol/l at screening.
Others:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dave Singh, Prof | Medicines Evaluation Unit, Manchester, United Kingdom | Principal Investigator |
| Rainard Fuhr, Dr | PAREXEL International GmbH EPCU Berlin | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Berlin | 14050 | Germany | |||
| Research Site |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
| Related Info | View source |
Not provided
A total of 103 patients were screened; 42 patients were eligible to participate and were randomised.
This study was conducted at two centres, one each in Germany and the UK. The first patient was enrolled in December 2016 and the last patient last visit was in August 2017.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | All Participants | All subjects received AZD8871 100 µg, AZD8871 600 µg or placebo, once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products. Each subject was randomized to one of three sequences in a 3-way, complete crossover William's design, and received all 3 treatments in turn, in three 14-day treatment periods, each (except the last one) followed by a wash-out period of 28-35 days. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Safety analysis set: Includes all randomised participants who received at least one dose of investigational product.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Overall Study Population | Full analysis set: All randomised participants who received at least one dose of investigational product. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in trough FEV1 on Day 15 | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | L | On Day 15 |
|
From screening to Follow-up/early termination Visit, 28 to 35 days after the last administration of investigational product (IP)
All reported AEs, date of onset, date of resolution, Investigator's assessment of severity, outcome, action taken with IP, and relationship to the IP were listed.
Non-Treatment-emergent adverse event (non-TEAE): any AE occurring before the first dose of IP, or >30 days after the last dose TEAE: event occurring after first dose of IP or present prior to the first dose, but increasing in severity after IP administration.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | AZD8871 100 µg | The subjects received AZD8871 100 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal wall abscess | Infections and infestations | MedDRA version 20.0 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA version 20.0 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr Ioannis Psallidas, MD, PhD | AstraZeneca | 1-877-240-9479 | Information.centre@astrazeneca.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Dec 16, 2016 | Aug 10, 2018 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jun 26, 2017 | Aug 10, 2018 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| C000656189 | AZD-8871 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| AZD8871 600 µg | Drug | The subjects will receive AZD8871, 600 µg single dose DPI. |
|
| Placebo | Drug | The subject will receive Placebo single dose DPI. |
|
Observed maximum concentration, taken directly from the individual concentration-time curve, on Day 14 of each treatment period. |
| Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 14. |
| Time to Reach Maximum Plasma Concentration (Tmax) of AZD8871 and Its Metabolites (Single Dose) | Time to reach maximum concentration taken directly from the individual concentration-time curve on Day 1 of each treatment period. | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1. |
| Time to Reach Maximum Plasma Concentration (Tmax) of AZD8871 and Its Metabolites (Multiple Doses, Day 14) | Time to reach maximum concentration taken directly from the individual concentration-time curve on Day 14 of each treatment period. | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 14. |
| AUClast of AZD8871 and Its Metabolites (Single Dose) | Area under the plasma concentration-curve from time zero to the last quantifiable time point (24 hours post-dose) calculated on Day 1 of each treatment period. | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1. |
| AUClast of AZD8871 and Its Metabolites (Multiple Doses, Day 14) | Area under the plasma concentration-curve from time zero to the last quantifiable time point (24 hours post-dose) calculated on Day 14 of each treatment period. | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 14. |
| AUC0-24 of AZD8871 and Its Metabolites (Single Dose) | Area under the plasma concentration-curve from time zero to 24 hours post-dose calculated on Day 1 of each treatment period. | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1. |
| AUC0-24 of AZD8871 and Its Metabolites (Multiple Doses, Day 14) | Area under the plasma concentration-curve from time zero to 24 hours post-dose calculated on Day 14 of each treatment period. | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 14. |
| Accumulation Ratio for Cmax (RacCmax) of AZD8871 and Its Metabolites (Day 14) | Accumulation ratio for Cmax estimated as (Cmax on Day 14 / Cmax on Day 1) in each treatment period. | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1 and Day 14. |
| Accumulation Ratio for AUC0-24 (RacAUC[0-24]) of AZD8871 and Its Metabolites (Day 14) | Accumulation ratio for AUC0-24 estimated as AUC0-24 on Day 14 / AUC0-24 on Day 1 in each treatment period. | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1 and Day 14. |
| Cavg of AZD8871 and Its Metabolites During a Dosing Interval (Day 14) | Average plasma concentration during a dosing interval calculated on Day 14 of each treatment period. | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 14. |
| Change From Baseline in Trough FEV1 at Day 1 (Single Dose) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in trough FEV1 on Day 1 | on Day 1 |
| Change From Baseline in Trough FEV1 at Day 8 (Pre-dose) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in trough FEV1 on Day 8 (pre-dose) | on Day 8 (pre-dose) |
| Change From Baseline in Trough FEV1 Over the Treatment Duration (Days 1-15) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in trough FEV1 over the treatment duration from Day 1 to Day 15 | Days 1-15 |
| Change From Baseline in Peak FEV1 at Day 1 (Single Dose) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in Peak FEV1 | on Day 1 |
| Change From Baseline in Peak FEV1 at Day 8 | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in Peak FEV1 | on Day 8 |
| Change From Baseline in Peak FEV1 at Day 14 | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in Peak FEV1 | on Day 14 |
| Change From Baseline in Peak FEV1 Over the Treatment Duration (Days 1-15) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in Peak FEV1 | over the treatment duration (Days 1-15) |
| Change From Baseline in BCSS Questionnaire Total Score From Day 1 to Day 8 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change from baseline in Total score of the Breathlessness, Cough Sputum Scale (BCSS) questionnaire. The BCSS questionnaire is a 3-item patient-reported outcome measure. On a daily basis, patients rated 3 symptoms (breathlessness, cough and sputum) on a 5-point Likert scale (range 0-4, high scores indicating higher severity). The BCSS questionnaire Total Score is the sum of the 3 symptom scores, ranging from 0-12 (lowest-highest severity). | From Day 1 to Day 8 post-treatment |
| Change From Baseline in BCSS Questionnaire Total Score From Day 9 to Day 14 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change from baseline in Total score of the Breathlessness, Cough Sputum Scale (BCSS) questionnaire. The BCSS questionnaire is a 3-item patient-reported outcome measure. On a daily basis, patients rated 3 symptoms (breathlessness, cough and sputum) on a 5-point Likert scale (range 0-4, high scores indicating higher severity). The BCSS questionnaire Total Score is the sum of the 3 symptom scores, ranging from 0-12 (lowest-highest severity). | From Day 9 to Day 14 post-treatment |
| Change From Baseline in Cough Individual Domain Score From Day 1 to Day 8 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire cough individual domain scores. On a daily basis, patients rated cough symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | From Day 1 to Day 8 post-treatment |
| Change From Baseline in Cough Individual Domain Score From Day 9 to Day 14 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire cough individual domain scores. On a daily basis, patients rated cough symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | From Day 9 to Day 14 post-treatment |
| Change From Baseline in Breathlessness Individual Domain Score From Day 1 to Day 8 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire breathlessness individual domain scores. On a daily basis, patients rated breathlessness symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | From Day 1 to Day 8 post-treatment |
| Change From Baseline in Breathlessness Individual Domain Score From Day 9 to Day 14 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire breathlessness individual domain scores. On a daily basis, patients rated breathlessness symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | From Day 9 to Day 14 post-treatment |
| Change From Baseline in Sputum Individual Domain Score From Day 1 to Day 8 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire sputum individual domain scores. On a daily basis, patients rated sputum symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | From Day 1 to Day 8 post-treatment |
| Change From Baseline in Sputum Individual Domain Score From Day 9 to Day 14 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire sputum individual domain scores. On a daily basis, patients rated sputum symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | From Day 9 to Day 14 post-treatment |
| Manchester |
| M23 9QZ |
| United Kingdom |
| Years |
|
| Sex/Gender, Customized | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
The subjects received AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
| OG002 | Placebo | The placebo was administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient received one inhaled dose from placebo DPI provided to him/her on each day of the treatment period. |
|
|
|
| Secondary | Observed Maximum Plasma (Cmax) of AZD8871 and Its Metabolites (Single Dose) | Observed maximum concentration, taken directly from the individual concentration-time curve, on Day 1 of each treatment period. | Pharmacokinetic analysis set: defined as all patients in the safety analysis set who received at least 1 dose of AZD8871 (100 μg or 600 μg), had at least 1 evaluable parameter out of Cmax, AUC or AUClast for AZD8871, and were assumed not to be affected by factors such as protocol deviations. | Posted | Geometric Mean | Geometric Coefficient of Variation | pg/mL | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1. |
|
|
|
| Secondary | Observed Maximum Plasma (Cmax) of AZD8871 and Its Metabolites (Multiple Doses, Day 14) | Observed maximum concentration, taken directly from the individual concentration-time curve, on Day 14 of each treatment period. | Pharmacokinetic analysis set: defined as all patients in the safety analysis set who received at least 1 dose of AZD8871 (100 μg or 600 μg), had at least 1 evaluable parameter out of Cmax, AUC or AUClast for AZD8871, and were assumed not to be affected by factors such as protocol deviations. | Posted | Geometric Mean | Geometric Coefficient of Variation | pg/mL | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 14. |
|
|
|
| Secondary | Time to Reach Maximum Plasma Concentration (Tmax) of AZD8871 and Its Metabolites (Single Dose) | Time to reach maximum concentration taken directly from the individual concentration-time curve on Day 1 of each treatment period. | Pharmacokinetic analysis set: defined as all patients in the safety analysis set who received at least 1 dose of AZD8871 (100 μg or 600 μg), had at least 1 evaluable parameter out of Cmax, AUC or AUClast for AZD8871, and were assumed not to be affected by factors such as protocol deviations. | Posted | Median | Full Range | h | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1. |
|
|
|
| Secondary | Time to Reach Maximum Plasma Concentration (Tmax) of AZD8871 and Its Metabolites (Multiple Doses, Day 14) | Time to reach maximum concentration taken directly from the individual concentration-time curve on Day 14 of each treatment period. | Pharmacokinetic analysis set: defined as all patients in the safety analysis set who received at least 1 dose of AZD8871 (100 μg or 600 μg), had at least 1 evaluable parameter out of Cmax, AUC or AUClast for AZD8871, and were assumed not to be affected by factors such as protocol deviations. | Posted | Median | Full Range | h | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 14. |
|
|
|
| Secondary | AUClast of AZD8871 and Its Metabolites (Single Dose) | Area under the plasma concentration-curve from time zero to the last quantifiable time point (24 hours post-dose) calculated on Day 1 of each treatment period. | Pharmacokinetic analysis set: defined as all patients in the safety analysis set who received at least 1 dose of AZD8871 (100 μg or 600 μg), had at least 1 evaluable parameter out of Cmax, AUC or AUClast for AZD8871, and were assumed not to be affected by factors such as protocol deviations. | Posted | Geometric Mean | Geometric Coefficient of Variation | pg*h/mL | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1. |
|
|
|
| Secondary | AUClast of AZD8871 and Its Metabolites (Multiple Doses, Day 14) | Area under the plasma concentration-curve from time zero to the last quantifiable time point (24 hours post-dose) calculated on Day 14 of each treatment period. | Pharmacokinetic analysis set: defined as all patients in the safety analysis set who received at least 1 dose of AZD8871 (100 μg or 600 μg), had at least 1 evaluable parameter out of Cmax, AUC or AUClast for AZD8871, and were assumed not to be affected by factors such as protocol deviations. | Posted | Geometric Mean | Geometric Coefficient of Variation | pg*h/mL | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 14. |
|
|
|
| Secondary | AUC0-24 of AZD8871 and Its Metabolites (Single Dose) | Area under the plasma concentration-curve from time zero to 24 hours post-dose calculated on Day 1 of each treatment period. | Pharmacokinetic analysis set: defined as all patients in the safety analysis set who received at least 1 dose of AZD8871 (100 μg or 600 μg), had at least 1 evaluable parameter out of Cmax, AUC or AUClast for AZD8871, and were assumed not to be affected by factors such as protocol deviations. | Posted | Geometric Mean | Geometric Coefficient of Variation | pg*h/mL | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1. |
|
|
|
| Secondary | AUC0-24 of AZD8871 and Its Metabolites (Multiple Doses, Day 14) | Area under the plasma concentration-curve from time zero to 24 hours post-dose calculated on Day 14 of each treatment period. | Pharmacokinetic analysis set: defined as all patients in the safety analysis set who received at least 1 dose of AZD8871 (100 μg or 600 μg), had at least 1 evaluable parameter out of Cmax, AUC or AUClast for AZD8871, and were assumed not to be affected by factors such as protocol deviations | Posted | Geometric Mean | Geometric Coefficient of Variation | pg*h/mL | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 14. |
|
|
|
| Secondary | Accumulation Ratio for Cmax (RacCmax) of AZD8871 and Its Metabolites (Day 14) | Accumulation ratio for Cmax estimated as (Cmax on Day 14 / Cmax on Day 1) in each treatment period. | Pharmacokinetic analysis set: defined as all patients in the safety analysis set who received at least 1 dose of AZD8871 (100 μg or 600 μg), had at least 1 evaluable parameter out of Cmax, AUC or AUClast for AZD8871, and were assumed not to be affected by factors such as protocol deviations. | Posted | Mean | Full Range | pg/mL | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1 and Day 14. |
|
|
|
| Secondary | Accumulation Ratio for AUC0-24 (RacAUC[0-24]) of AZD8871 and Its Metabolites (Day 14) | Accumulation ratio for AUC0-24 estimated as AUC0-24 on Day 14 / AUC0-24 on Day 1 in each treatment period. | Pharmacokinetic analysis set: defined as all patients in the safety analysis set who received at least 1 dose of AZD8871 (100 μg or 600 μg), had at least 1 evaluable parameter out of Cmax, AUC or AUClast for AZD8871, and were assumed not to be affected by factors such as protocol deviations. | Posted | Mean | Full Range | pg*h/mL | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 1 and Day 14. |
|
|
|
| Secondary | Cavg of AZD8871 and Its Metabolites During a Dosing Interval (Day 14) | Average plasma concentration during a dosing interval calculated on Day 14 of each treatment period. | Pharmacokinetic analysis set: defined as all patients in the safety analysis set who received at least 1 dose of AZD8871 (100 μg or 600 μg), had at least 1 evaluable parameter out of Cmax, AUC or AUClast for AZD8871, and were assumed not to be affected by factors such as protocol deviations. | Posted | Geometric Mean | Geometric Coefficient of Variation | pg/mL | Pre-dose and 30 min, 1, 2, 4, 6, 8, 12, and 24 hours post-dose on Day 14. |
|
|
|
| Secondary | Change From Baseline in Trough FEV1 at Day 1 (Single Dose) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in trough FEV1 on Day 1 | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | L | on Day 1 |
|
|
|
|
| Secondary | Change From Baseline in Trough FEV1 at Day 8 (Pre-dose) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in trough FEV1 on Day 8 (pre-dose) | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | L | on Day 8 (pre-dose) |
|
|
|
|
| Secondary | Change From Baseline in Trough FEV1 Over the Treatment Duration (Days 1-15) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in trough FEV1 over the treatment duration from Day 1 to Day 15 | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | L | Days 1-15 |
|
|
|
|
| Secondary | Change From Baseline in Peak FEV1 at Day 1 (Single Dose) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in Peak FEV1 | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | L | on Day 1 |
|
|
|
|
| Secondary | Change From Baseline in Peak FEV1 at Day 8 | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in Peak FEV1 | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | L | on Day 8 |
|
|
|
|
| Secondary | Change From Baseline in Peak FEV1 at Day 14 | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in Peak FEV1 | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | L | on Day 14 |
|
|
|
|
| Secondary | Change From Baseline in Peak FEV1 Over the Treatment Duration (Days 1-15) | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change in Peak FEV1 | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | L | over the treatment duration (Days 1-15) |
|
|
|
|
| Secondary | Change From Baseline in BCSS Questionnaire Total Score From Day 1 to Day 8 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change from baseline in Total score of the Breathlessness, Cough Sputum Scale (BCSS) questionnaire. The BCSS questionnaire is a 3-item patient-reported outcome measure. On a daily basis, patients rated 3 symptoms (breathlessness, cough and sputum) on a 5-point Likert scale (range 0-4, high scores indicating higher severity). The BCSS questionnaire Total Score is the sum of the 3 symptom scores, ranging from 0-12 (lowest-highest severity). | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | Scores on a scale | From Day 1 to Day 8 post-treatment |
|
|
|
|
| Secondary | Change From Baseline in BCSS Questionnaire Total Score From Day 9 to Day 14 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD was assessed by measuring the change from baseline in Total score of the Breathlessness, Cough Sputum Scale (BCSS) questionnaire. The BCSS questionnaire is a 3-item patient-reported outcome measure. On a daily basis, patients rated 3 symptoms (breathlessness, cough and sputum) on a 5-point Likert scale (range 0-4, high scores indicating higher severity). The BCSS questionnaire Total Score is the sum of the 3 symptom scores, ranging from 0-12 (lowest-highest severity). | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | Scores on a scale | From Day 9 to Day 14 post-treatment |
|
|
|
|
| Secondary | Change From Baseline in Cough Individual Domain Score From Day 1 to Day 8 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire cough individual domain scores. On a daily basis, patients rated cough symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | Scores on a scale | From Day 1 to Day 8 post-treatment |
|
|
|
|
| Secondary | Change From Baseline in Cough Individual Domain Score From Day 9 to Day 14 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire cough individual domain scores. On a daily basis, patients rated cough symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | Scores on a scale | From Day 9 to Day 14 post-treatment |
|
|
|
|
| Secondary | Change From Baseline in Breathlessness Individual Domain Score From Day 1 to Day 8 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire breathlessness individual domain scores. On a daily basis, patients rated breathlessness symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | Scores on a scale | From Day 1 to Day 8 post-treatment |
|
|
|
|
| Secondary | Change From Baseline in Breathlessness Individual Domain Score From Day 9 to Day 14 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire breathlessness individual domain scores. On a daily basis, patients rated breathlessness symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | Scores on a scale | From Day 9 to Day 14 post-treatment |
|
|
|
|
| Secondary | Change From Baseline in Sputum Individual Domain Score From Day 1 to Day 8 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire sputum individual domain scores. On a daily basis, patients rated sputum symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | Scores on a scale | From Day 1 to Day 8 post-treatment |
|
|
|
|
| Secondary | Change From Baseline in Sputum Individual Domain Score From Day 9 to Day 14 Post-treatment | The efficacy of inhaled AZD8871 in patients with moderate to severe COPD will be assessed by measuring the change from baseline in Breathlessness, Cough Sputum Scale (BCSS) questionnaire sputum individual domain scores. On a daily basis, patients rated sputum symptoms on a 5-point Likert scale (range 0-4, high scores indicating higher severity). | Full analysis set (FAS): all randomised patients who received at least one dose of the IP, irrespective of their protocol adherence and continued participation in the study. | Posted | Least Squares Mean | Standard Error | Scores on a scale | From Day 9 to Day 14 post-treatment |
|
|
|
|
| 0 |
| 34 |
| 0 |
| 34 |
| 5 |
| 34 |
| EG001 | AZD8871 600 µg | The subjects received AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products. | 0 | 39 | 1 | 39 | 7 | 39 |
| EG002 | Placebo | The placebo was administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient received one inhaled dose from placebo DPI provided to him/her on each day of the treatment period. | 0 | 36 | 1 | 36 | 5 | 36 |
| Appendicitis | Infections and infestations | MedDRA version 20.0 | Systematic Assessment |
|
| Chronic obstructive pulmonary disease exacerbation | Respiratory, thoracic and mediastinal disorders | MedDRA version 20.0 | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA version 20.0 | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA version 20.0 | Systematic Assessment |
|
| Viral upper respiratory tract infections | Infections and infestations | MedDRA version 20.0 | Systematic Assessment |
|
Publication and / or presentation whether complete or partial, of any part of the data or results of this study will not be allowed until global publication and study results disclosure by the sponsor as per EMA / FDA regulatory compliance obligations, and only after mutual agreement between the Investigator and AstraZeneca
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| LAS34850 |
|
| LAS191861 |
|
|
| LAS34850 |
|
|
| LAS34850 |
|
| LAS191861 |
|
|
| LAS34850 |
|
|
| LAS191861 |
|
|
| LAS34850 |
|
|
| LAS191861 |
|
|
| LAS34850 |
|
|
| LAS191861 |
|
|
| LAS34850 |
|
|
| LAS191861 |
|
|
| LAS34850 |
|
|
| LAS191861 |
|
|
| LAS34850 |
|
|
| LAS191861 |
|
|
| LAS34850 |
|
|
| LAS191861 |
|
|
| LAS34850 |
|
|
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| <0.001 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.011 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| <0.001 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.201 | Superiority |
Comparison of AZD8871 600 µg vs placebo
| ANCOVA |
Fixed effect: treatment, sequence, period, treatment*day. Repeat factor: day. Random effect: patient nested in sequence. Continuous covar: baseline. |
| <0.001 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effect: treatment, sequence, period, treatment*day. Repeat factor: day. Random effect: patient nested in sequence. Continuous covar: baseline. | 0.020 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| <0.001 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | <0.001 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| <0.001 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.092 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| <0.001 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.279 | Superiority |
Comparison of AZD8871 600 µg vs placebo
| ANCOVA |
Fixed effect: treatment, sequence, period, treatment*day. Repeat factor: day. Random effect: patient nested in sequence. Continuous covar: baseline. |
| <0.001 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effect: treatment, sequence, period, treatment*day. Repeat factor: day. Random effect: patient nested in sequence. Continuous covar: baseline. | <0.001 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| 0.002 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.060 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| <0.001 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.015 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| 0.138 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.333 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| 0.005 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.013 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| <0.001 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.030 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| <0.001 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.047 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| 0.014 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.084 | Superiority |
| ANCOVA |
Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. |
| 0.001 |
| Superiority |
| Comparison of AZD8871 600 µg vs AZD8871 100 µg | ANCOVA | Fixed effects: treatment, sequence, period. Random effect for patient nested within sequence. Continuous covariate: baseline. | 0.046 | Superiority |